Skip to main content

Mesothelioma Clinical Trials

Review the mesothelioma clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-22 of 22

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Status: Active
Location: 11 locations
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Status: Active
Location: 10 locations
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Status: Active
Location: 8 locations
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Status: Active
Location: 7 locations
A Study of BMS-986504 with Standard-of-Care Therapy for the Treatment of Patients with Advanced, Metastatic or Unresectable Solid Tumor Cancer with MTAP Loss
Status: Active
Location: 7 locations
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Status: Active
Location: 9 locations
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Status: Active
Location: 9 locations
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Status: Active
Location: 3 locations
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Status: Active
Location: 2 locations
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Status: Active
Location: 2 locations
Olaparib for the Treatment of Homologous Recombination Deficient Malignant Mesothelioma
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Durvalumab and Tremelimumab with or without Chemotherapy for the Treatment of Potentially Resectable Pleural Mesothelioma
Status: Active
Location: Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas
CD70 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells and Lymphodepleting Chemotherapy for the Treatment of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Pembrolizumab in Combination with Chemotherapy and Image-Guided Surgery for the Treatment of Resectable Pleural Malignant Mesothelioma (MPM)
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
A Surgical Procedure (Partial Pleurectomy and Decortication) for the Treatment of Borderline Resectable and Unresectable Pleural Mesothelioma
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
ALG.APV-527 First-in-human Study
Status: Active
Location: See ClinicalTrials.gov
Vudalimab for the Treatment of Advanced Rare Cancers
Status: Temporarily Closed to Accrual
Location: UT MD Anderson Cancer Center, Houston, Texas
Atezolizumab and Bevacizumab in Treating Patients with Rare Solid Tumors
Status: Temporarily Closed to Accrual
Location: UT MD Anderson Cancer Center, Houston, Texas
Genetic Testing on Blood Samples for Treatment Suggestions in Patients with Advanced or Metastatic Cancer
Status: Active
Location: 4 locations
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland